Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2023-03-15 Director's Dealing
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing Classification · 98% confidence The document explicitly begins with the header "# **FORM 4**" and references the "UNITED STATES SECURITIES AND EXCHANGE COMMISSION". Form 4 is the standard SEC filing used to report changes in beneficial ownership of securities by company insiders (directors, officers, or 10% owners). This filing type is specifically for reporting insider transactions, which aligns with the category 'Director's Dealing' (DIRS) in the provided definitions, as it details transactions by an officer (President and CEO) of the issuer. Although the SEC filing itself is Form 4, among the provided classification codes, 'DIRS' (Director's Dealing) is the most appropriate fit for insider transaction reports.
2023-03-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing Classification · 95% confidence The document is a filing from ORAMED PHARMACEUTICALS INC, reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange. The key indicator is the line: "Attached hereto is a report on *Form 4 - Nadav Kidron*". Form 4 in the US context (which this foreign issuer references) typically relates to insider transactions (Director's Dealing). However, the provided definitions do not have a specific code for 'Form 4'. The document explicitly states it is an 'Other Report or Announcement' under Regulation 5. Since the content strongly suggests a report about an insider transaction (Form 4), and the document itself is very short (1885 chars) and announces an attachment, it could potentially be an RPA if it were just announcing a standard filing. Given the specific nature of 'Form 4' which relates to insider transactions, and the presence of a signatory who is the Chief Legal Officer & Secretary, this is most closely related to insider activity. The closest defined category for insider transactions is 'Director's Dealing' (DIRS). Since this is an official announcement/report submission rather than a full annual report or earnings release, and it concerns executive activity, DIRS is the most appropriate fit among the specific options, even if the exact form name isn't listed. If DIRS were not available, RNS would be the fallback, but DIRS is more specific to the content implied by 'Form 4'. I will classify it as DIRS based on the nature of Form 4 filings.
2023-03-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing Classification · 99% confidence The document explicitly begins with the header "FORM 4" and the title "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES". This form is filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 by directors, officers, or 10% owners of a company to report transactions in the issuer's securities. This specific filing type corresponds to reporting insider trades by directors/executives, which matches the definition for Director's Dealing (DIRS). Although the document is a regulatory filing, DIRS is the most specific category available for Form 4 filings.
2023-03-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing Classification · 95% confidence The document explicitly states it is an 'Other Report or Announcement' filed under Israeli regulations ('Israel Securities Authority', 'Reported via MAGNA'). Crucially, it states: 'Attached hereto is a report on *Form 4 - Miriam Kidron*'. Form 4 in the US context (and implied here given the NASDAQ listing and US address) is a statement of changes in beneficial ownership, which corresponds to insider trading activity by directors or executives. This aligns directly with the definition for Director's Dealing (DIRS). Although the document is short and announces an attachment (suggesting RPA/RNS), the specific content points to a mandatory insider transaction report (Form 4), which is a specific type of insider filing that fits best under DIRS, rather than a generic regulatory filing (RNS) or a report publication announcement (RPA) which usually announces a larger report like a 10-K or IR. Given the specific nature of the attached Form 4, DIRS is the most accurate classification.
2023-03-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing Classification · 100% confidence The document explicitly displays the header "FORM 4" and "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES". Form 4 is the standard SEC filing used by corporate insiders (directors, officers, or 10% owners) to report transactions in the company's securities. This directly corresponds to the definition of Director's Dealing (insider trades). Reviewing the provided definitions, 'Director's Dealing (Code: DIRS)' is the most appropriate classification for an SEC Form 4 filing.
2023-03-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing Classification · 95% confidence The document is a filing from ORAMED PHARMACEUTICALS INC, reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange on 15/03/2023. The key indicator is the line: "Attached hereto is a report on *Form 4 - Yadin Rozov*" followed by a reference to a PDF file. Form 4 in the US context (and this document mentions NASDAQ CM and US address) typically relates to insider transactions (Director's Dealing). However, the provided definitions do not explicitly list SEC Form 4. I must check the definitions against the content. The content explicitly mentions a report attached and names a signatory (DEROVAN NETANEL MOSHE, Chief Legal Officer & Secretary) reporting a transaction. This strongly suggests insider trading disclosure, which aligns best with the 'Director's Dealing' category (DIRS). Since this is an announcement attaching a specific report (Form 4), and not the full annual report (10-K) or an earnings release (ER), DIRS is the most specific fit for insider transaction reporting, even if it's a regulatory filing from a foreign issuer.
2023-03-15 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.